SK Bioscience Passes Preliminary Review for KOSPI Listing
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2021012213530040006_1611291181.jpg)
[Asia Economy Reporter Lim Chun-han] The Korea Exchange announced on the 4th that SK Bioscience has met the requirements in the preliminary review for listing on the KOSPI market and has been confirmed as eligible for listing.
Established in July 2018 as a spin-off from SK Chemicals, SK Bioscience manufactures influenza vaccines, shingles vaccines, and other products. Currently, SK Chemicals holds a 98% stake in the company.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
As of 2019, the company reported sales of 183.9 billion KRW and a net profit of 14.7 billion KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
